Is ARKG a Good Investment? The Case For and Against (2026)
Last updated November 2026
Short answer
The case for ARKG is simple: low-cost, diversified exposure to Actively managed (no index); focused on genomics and biotech innovation at a 0.75% expense ratio, anchored by names like TWST, TXG, TEM. If that is the exposure you want and you do not already own most of it through another fund, ARKG is a strong core holding. The trade-offs are concentration in its top names and overlap with broad-market funds you may already hold. Whether it is a buy comes down to whether you want Actively managed (no index); focused on genomics and biotech innovation and at what cost. Not a recommendation; Walnut is not an investment adviser.
What are you buying with ARKG?
The ARK Genomic Revolution ETF (ARKG) is an actively-managed fund from Cathie Wood's ARK Invest that targets companies it believes will benefit from advances in genomics, gene editing, molecular diagnostics, and biotechnology. The portfolio is highly concentrated, typically holding around 30 to 35 names, with the top 10 positions making up roughly two-thirds of assets as of October 2026. It tilts heavily toward early-stage, pre-profit and clinical-stage biotech names, including CRISPR gene-editing companies, molecular-diagnostics firms, and AI-driven drug discovery platforms. ARKG carries a 0.75% expense ratio and saw its assets fall sharply from a peak near $9 billion in early 2021 to roughly $1.2 billion in early 2026. Both outflows and a deep drawdown in speculative biotech drove that decline. 2026 brought a sharp rebound: as of October 16, 2026, ARKG's price was up 62.1% year to date and 47.4% over one year, and assets had recovered to about $2.2 billion, though the price fell 8.4% over the prior month.
Largest holdings (approximate as of October 2026; verify on ARK Invest's fund page):
What's the case for ARKG?
ARKG is Cathie Wood's actively-managed ARK Invest ETF focused on the genomics and biotech-innovation theme, holding names like Twist Bioscience, 10x Genomics, Tempus AI, CRISPR Therapeutics, and other molecular-diagnostics and gene-editing companies. It is highly concentrated, with around 30 to 35 holdings and the top 10 accounting for roughly two-thirds of assets in October 2026. The fund is very volatile and has suffered a large drawdown since its 2021 peak, with assets falling from about $9 billion to roughly $1.2 billion by early 2026 before recovering to about $2.2 billion by October 2026 as biotech rallied (the price was up 62.1% year to date as of October 16, 2026). It is a high-risk thematic fund built around speculative, often unprofitable biotech companies.
In its favour: it gives you Actively managed (no index); focused on genomics and biotech innovation exposure in one ticker at a 0.75% expense ratio, which is simple to hold and cheap to own.
What should you weigh before buying ARKG?
- Cost vs alternatives: 0.75% is the fee; compare it to funds tracking a similar index.
- Concentration: check how much of ARKG sits in its largest holdings (TWST, TXG, TEM).
- Overlap: if you already own a broad-market fund, you may already hold much of this.
- Tracking scope: ARKG only gives you Actively managed (no index); focused on genomics and biotech innovation; it will not capture what sits outside that index.
How concentrated is ARKG?
“Diversified” is the word every index fund uses and it hides a wide range. The number that actually matters is how much of the fund sits in its largest positions, because that is the part that drives the return. In ARKG, the three largest positions are about 29.2% of the fund and the 10 largest are about 62.3%, with the single biggest at roughly 10.3%. Those are approximate weights as of October 2026, and because this is only the published top 10, treat 62.3% as a floor on concentration. The full book could be more concentrated. Verify with ARK Invest.
ARKG is a concentrated fund. Most of what you own moves with a small number of companies, so ARKG behaves much more like a bet on those names than the word "index" suggests. That can be exactly what you want, as long as it is what you meant to buy.
The same number decides whether ARKG adds diversification to your portfolio in particular. A fund can be well spread on its own and still concentrate you further, if its largest holdings are names you already own directly or through another fund. Answering that means looking at your account as well as at ARKG, and it is the question to settle before you buy.
What ARKG does not give you
A fund is defined as much by what it leaves out as by what it holds, and the exclusions are rarely on the marketing page. ARKG tracks Actively managed (no index); focused on genomics and biotech innovation, so anything outside that index is simply absent from your portfolio no matter how much of the fund you own.
In practice that means checking three gaps. Whether the geography you want is covered, since a US index holds no international companies and a developed-markets index holds no emerging ones. Whether the size band you want is covered, because a large-cap index excludes the smaller companies some investors specifically want exposure to. And whether the asset class you want is covered at all, since an equity fund holds no bonds and gives you nothing to rebalance against in a drawdown.
None of these are faults; the fund is doing what it says. The mistake is assuming that owning a diversified fund means being diversified, when it means being diversified within one index.
When ARKG is the wrong choice
Some specific cases where it does not fit:
- You already own most of it. If a broad-market fund you hold already contains TWST, TXG, TEM at meaningful weight, adding ARKG mostly increases your exposure to the same companies while adding a second fee. Overlap like this is the single most common way people accidentally concentrate.
- You want the exposure for a short horizon. An index fund is a way to own an asset class over years. Over months it is simply the index, with all of the index's volatility and none of the compounding that makes holding it worthwhile.
- You need income you can rely on. Distributions from an equity index fund vary with what the underlying companies pay, so they are not a schedule you can plan around the way a bond ladder is.
- A cheaper fund tracks the same thing. Where two funds follow a similar index, the difference in expense ratio is one of the few advantages available to you without taking extra risk. Compare before assuming 0.75% is competitive.
How do you decide if ARKG is a buy?
The useful question is rarely “will ARKG go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how ARKG would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.
The bottom line on ARKG
The bottom line: ARKG is a low-cost core building block for Actively managed (no index); focused on genomics and biotech innovation exposure, not a tactical bet on a single name. If you want Actively managed (no index); focused on genomics and biotech innovation exposure and the 0.75% fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.
More on ARKG
- What is ARKG? (holdings, cost, performance, and the themes it covers)
- ARKG dividend: yield and schedule
- ARKG forecast: what analysts expect for its holdings
Your questions about ARKG
Ask Walnut's AI anything about ARKG and see how it fits what you own.
FAQ
Is ARKG a good ETF to buy?
+
Walnut is informational, not investment advice. Whether ARKG fits depends on your goals, time horizon, and what you already hold. It tracks Actively managed (no index); focused on genomics and biotech innovation at a 0.75% expense ratio, so the questions that matter are whether you want that exposure, whether you already own it through another fund, and whether the cost is competitive for what it does.
What does ARKG actually hold?
+
ARKG tracks Actively managed (no index); focused on genomics and biotech innovation. Its largest positions include TWST, TXG, TEM, CRSP, ABSI and others (approximate, verify on ARK Invest's fund page). The holdings are what you are really buying, not the ticker.
What is ARKG's expense ratio?
+
0.75% as of October 2026. Over decades, the expense ratio is one of the few things you can control, so compare it against close alternatives that track a similar index.
Does ARKG pay a dividend?
+
ARKG distributes a dividend with an approximate yield of 0.00% (does not currently pay a dividend) (October 2026). See the ARKG dividend page for how distributions work. Verify the current figure with ARK Invest.
What are the risks of buying ARKG?
+
Like any index ETF, weigh concentration (how much sits in the top holdings), overlap with funds you already own, and whether Actively managed (no index); focused on genomics and biotech innovation matches the exposure you actually want. ARKG only gives you Actively managed (no index); focused on genomics and biotech innovation, not what sits outside it.
How do I decide if ARKG is right for me?
+
Start from your goal, then check four things: what ARKG holds, its cost versus alternatives, how much it overlaps with what you already own, and whether the exposure fits your time horizon and risk tolerance. Walnut can analyze the overlap against your real holdings; you keep your broker and approve any trade.
Walnut is informational, not investment advice. Figures are approximations stamped to October 2026; verify current data with ARK Invest or your broker. Nothing here is a recommendation to buy, sell, or hold any security.